Clinical Trials Logo

Bruxism clinical trials

View clinical trials related to Bruxism.

Filter by:

NCT ID: NCT05784454 Not yet recruiting - Sleep Bruxism Clinical Trials

Prevalance of Sleep Bruxism Among a Group of Egyptian Children

Start date: May 2, 2023
Phase:
Study type: Observational

The goal of this observational study is to detect the prevalence of sleep bruxism in a group of Egyptian children and detect its relation to screen-time and sugar consumption. The main questions it aims to answer are: 1. In a group of Egyptian Children what is the prevalence of sleep bruxism? 2. What is the relation between sleep bruxism and screen time and sugar consumption?

NCT ID: NCT05769166 Not yet recruiting - Bruxism Clinical Trials

Prevalence Of Deleterious Oral Habits Among a Group of School Children in Cairo, Egypt: Cross-Sectional Study

ACU333
Start date: April 1, 2023
Phase:
Study type: Observational

This study aims to detect the prevalence of practicing oral habits among a group of school children in Cairo, Egypt.

NCT ID: NCT05764694 Not yet recruiting - Bruxism Clinical Trials

Correlation Between the Occurrence of School Bullying, Victimization, and the Occurrence of Deleterious Oral Habits.

Start date: September 1, 2023
Phase:
Study type: Observational

To determine the correlation between the occurrence of bullying, victimization, and deleterious oral habit in a group of Egyptian school children.

NCT ID: NCT05760482 Completed - Anxiety State Clinical Trials

Evaluation of the Relationship Between Bruxism and Tryptophan Metabolites

Start date: September 4, 2023
Phase: N/A
Study type: Interventional

Psychological causes are often cited as the most important of the underlying factors for bruxism. However, there are very few studies that can objectively demonstrate this. There are studies that are generally based on subjective data, that is, on questionnaires that indicate anxiety or stress. Recent studies have shown that tryptophan and its metabolites are associated with psychological health. In this study, researchers will measure the serum values of metabolites in the tryptophan pathway. Also, researchers will observe whether these metabolite levels differ significantly in patients with and without bruxism.

NCT ID: NCT05751694 Recruiting - Clinical trials for Gastroesophageal Reflux

Effectiveness of Visceral Manual Therapy in Bruxist Patients With Gastroesophageal Reflux

Start date: March 1, 2023
Phase: N/A
Study type: Interventional

Objective: check the effectiveness of visceral manual therapy on bruxist patients with gastroesophageal reflux. Design: Experimental, analytical, longitudinal, prospective, randomized, single-blind study with a blinded evaluator. Subjects: 68 subjects over 18 years old, with bruxism (diagnoses by a dentist) and gastroesophageal reflux (evidenced by the GERDQ test). Methods: Subjects will be randomized into 2 groups: an experimental group (EG) to which a visceral manual technique will be applied and a control group (CG) to which a placebo manual technique will be administered. Both groups will receive 2 interventions one week apart. The measurements will be made before and after the interventions, and a last measurement will be made one month after the last intervention. Therefore, the patient will visit the center 3 times.

NCT ID: NCT05657353 Completed - Bruxism Clinical Trials

Relation Between Bruxism and Cervical Function

Start date: December 8, 2022
Phase:
Study type: Observational

correlation between Bruxism and Cervical function

NCT ID: NCT05620316 Completed - Nocturnal Bruxism Clinical Trials

The Use of Low-Dose Botulinum Toxin Injection Into the Masseter Muscle to Treat Sleep Bruxism

Start date: March 15, 2021
Phase: N/A
Study type: Interventional

Botulinum toxin (BOTOX®) injections into the masseter muscle are an effective treatment for nocturnal bruxism, with several trials using various dosages of botulinum toxin for this purpose. The aim was to evaluate the effectiveness of injecting 10MU of botulinum toxin A (BTXA) into the masseter muscle to reduce nocturnal bruxism, the sample will randomly divided into 2 groups. In the injection group, Patients will inject with 10 MU of botulinum toxin type A (BOTOX® - Allergan Inc. - Dublin - Ireland) per side at two sites into the masseter muscle bilaterally. In this Placebo group, patients will prick twice at the inferior prominent part of the masseter muscle observed using the stinger pen used in the blood glucose meter. The evaluation will make by Electromyography (EMG) analysis, Visual Analogue Scale (VAS) values.

NCT ID: NCT05604729 Recruiting - Bruxism Clinical Trials

The Effect on Envelope of Motion in Asymptomatic Bruxers

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

Investigating the effect of botulinum neurotoxin on the jaw-neck envelope of motion.

NCT ID: NCT05594511 Recruiting - Clinical trials for Temporomandibular Joint Disorders

Mandibular Muscle Energy Technique in Patients With Mandibular Joint Pathology and Bruxism

Start date: April 25, 2022
Phase: N/A
Study type: Interventional

This is a randomized, controlled, double-blind clinical trial. The main objective is to evaluate the immediate effect of the mandibular muscle-energy technique on pain, functionality and kinesiophobia in subjects suffering from temporomandibular dysfunction and bruxism. In the experimental group the jaw muscle-energy technique will be applied and in the control group a placebo technique will be applied. The intention is to see the immediate effects of the intervention and two evaluations of the pre- and post-intervention outcome variables and a follow-up of kinesiophobia one week later will be performed.

NCT ID: NCT05562635 Recruiting - Clinical trials for Temporomandibular Disorder

CBD (Cannabidiol) Intraoral Application and TMD (Temporomandibular Disorders)

Start date: July 18, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

The aim of the project is to assess the effectiveness of reducing the masseter muscles tension and hyperactivity in patients with a painful form of TMD by using polymers containing CBD compared to placebo polymers.